Welcome to the WCN 2023 Interactive Program

Abstract Body

There has been great progress in understanding the biology of ALS and the development of more targeted treatments. In just the past year, three therapies have come to market; two for all forms of als and one for SOD1 mediated familial ALS. In addition, we launched the first platform trial in ALS, The HEALEY ALS Platform Trial and are now on the seventh drug. Results from the first four therapies will be shared including new biomarker data. A review of state of ALS trials will highlight innovations in design, biomarkers and therapy selection.